Shares of Avenue Therapeutics Inc (ATXI) are trading 37% higher at a price of $13.79 at the time of this writing. The market is undergoing a significant macro move (2.02%) which could be a factor in the stock's movement.
Avenue Therapeutics Inc has been trading between a 52-week high of $27.75 and a 52-week low of $3. The stock has a market cap of $303 Million.
Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc.